Secondary Dyslipidemia

Henkin, Yaakov; Como, Jackson A.; Oberman, Albert

doi:10.1001/jama.1992.03480070077035

Cited by 69 publications

(5 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corticosteroids appear to elevate all the lipoprotein cholesterol levels. [ 37 ] This is explained in part due to the relative adrenocorticotropic hormone (ACTH) deficiency caused by long-term steroid intake. Corticosteroids are a main stay of therapy for pemphigus and many other autoimmune and inflammatory diseases.…”

Section: Dermatological Drugs Inducing Dyslipidemiamentioning

confidence: 99%

Dyslipidemia in dermatological disorders

Shenoy

Rao

2015

North Am J Med Sci

View full text Add to dashboard Cite

Dyslipidemias are one of the common metabolic disorders. A link between dermatological disorders like psoriasis and dyslipidemia has been established in the recent past. Many dermatological disorders could have a systemic inflammatory component which explains such association. Chronic inflammatory dermatological disorders could also have other metabolic imbalances that may contribute to dyslipidemia. Presence of such abnormal metabolism may justify routine screening of these disorders for associated dyslipidemia and other metabolic abnormalities and early treatment of such comorbidities to improve quality of life. Some of the drugs used by dermatologists such as retinoids are also likely to be a cause of dyslipidemia. Hence, it is imperative that the dermatologists obtain scientific knowledge on the underlying mechanisms involved in dyslipidemia and understand when to intervene with therapies. A systematic review of the English language literature was done by using Google Scholar and PubMed. In this review, attempts are made to list the dermatological disorders associated with dyslipidemia; to simplify the understanding of underlying mechanisms; and to give a brief idea about the interventions.

show abstract

Section: Dermatological Drugs Inducing Dyslipidemiamentioning

confidence: 99%

Dyslipidemia in dermatological disorders

Shenoy

Rao

2015

North Am J Med Sci

View full text Add to dashboard Cite

show abstract

“…Although little information is available on the effects of these analgesics on the lipid profile, frequent use of NSAIDs or acetaminophen has been associated with a significantly increased risk of CV events [ 133 ], with nonaspirin (acetylsalicylic acid) NSAIDs increasing the chance of a heart attack or stroke. Aspirin is a more selective COX-1 inhibitor that has been shown to slightly decrease TG levels [ 131 , 134 ] and have moderate benefits on CVD-related factors, reducing the risk of stroke but not CHD [ 131 ]. Excessive use of NSAIDs has been linked to acute CKD [ 135 , 136 ].…”

Section: Introductionmentioning

confidence: 99%

Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?

Rosenblit

2016

Cardiovasc Diabetol

View full text Add to dashboard Cite

Dyslipidemia is the most fundamental risk factor for atherosclerotic cardiovascular disease (ASCVD). In clinical practice, many commonly prescribed medications can alter the patient’s lipid profile and, potentially, the risk for ASCVD—either favorably or unfavorably. The dyslipidemia observed in type 2 diabetes mellitus (T2DM) can be characterized as both ominous and cryptic, in terms of unrecognized, disproportionately elevated atherogenic cholesterol particle concentrations, in spite of deceptively and relatively lower levels of low-density lipoprotein cholesterol (LDL-C). Several factors, most notably insulin resistance, associated with the unfavorable discordance of elevated triglyceride (TG) levels and low levels of high-density lipoprotein cholesterol (HDL-C), have been shown to correlate with an increased risk/number of ASCVD events in patients with T2DM. This review focuses on known changes in the routine lipid profile (LDL-C, TGs, and HDL-C) observed with commonly prescribed medications for patients with T2DM, including antihyperglycemic agents, antihypertensive agents, weight loss medications, antibiotics, analgesics, oral contraceptives, and hormone replacement therapies. Given that the risk of ASCVD is already elevated for patients with T2DM, the use of polypharmacy may warrant close observation of overall alterations through ongoing lipid-panel monitoring. Ultimately, the goal is to reduce levels of atherogenic cholesterol particles and thus the patient’s absolute risk.

show abstract

“…Some traditional risk factors may also interact with management of SLE disease activity; for example smoking decreases responsiveness to antimalarial therapy [18, 19]. Some risks like diabetes and hyperlipidemia may also be increased as secondary effects of glucocorticoid therapy [20], while others may be directly influenced by SLE disease activity itself. For instance, high levels of very low density lipoprotein (VLDL) and triglycerides (TG) and low levels of high density lipoprotein (HDL) have been described as the “lupus pattern,” and are more strikingly noted in patients with active disease [21].…”

Section: Identification Of Sle Patients At Risk For Cardiovascular Evmentioning

confidence: 99%